How can we increase the efficacy of vaccines used to protect against viral respiratory diseases such as influenza and COVID-19? Scientists from Inserm, CNRS and Aix-Marseille Université at the Center of Immunology Marseille-Luminy are opening up new prospects in the field, with ...
De récents résultats montrent que dans la lutte contre le sepsis, il ne faut pas seulement tuer les bactéries en cause, mais réduire aussi leur capacité à produire des vésicules de quelques dizaines de nanomètres (appelées OMV pour Outer Membrane Vesicle en ...
Rémi Quirion, Quebec’s Chief Scientist, and Dr. Gilles Bloch, Chairman and Chief Executive Officer of the French National Institute of Health and Medical Research (Inserm), are pleased to announce the signing of a new joint Declaration of Intent between the Quebec Health Research ...
A very small percentage of people with HIV-1, known as "post-treatment controllers" (PTCs), are able to control their infection after interrupting all antiretroviral therapy. Understanding the fundamental mechanisms that govern their immune response is essential in order to develop HIV-1 vaccines, novel ...
Sorry, this entry is only available in French.[credits]Co-marquages de peau de souris exprimant une mutation du gène PIK3CA. ©Marina Firpion/Guillaume Canaud – unité 1151 Inserm[/credits]L’AP-HP, l’Inserm et Université Paris ...
Researchers have studied the impact of individual sociodemographic, behavioral and health factors on the practice of daily physical activity in later life, using data from 3,896 participants of the Whitehall II cohort. This research highlights the complexity of individual barriers to an active ...
Les leucémies regroupent plusieurs types de cancer du sang qui affectent chaque année en France jusqu’à 10 000 personnes. Parmi les traitements proposés : la greffe de cellules souches hématopoïétiques. Ces cellules fabriquées par la moelle osseuse sont à l'origine des différentes cellules du ...